Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effect of race/ethnicity on cancer-specific mortality after salvage radical prostatectomy

M. Wenzel, C. Würnschimmel, L. Nocera, C. Colla Ruvolo, B. Hoeh, Z. Tian, SF. Shariat, F. Saad, A. Briganti, M. Graefen, F. Preisser, A. Becker, P. Mandel, FKH. Chun, PI. Karakiewicz

. 2022 ; 12 (-) : 874945. [pub] 20220819

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023485

Background: To test the effect of race/ethnicity on cancer-specific mortality (CSM) after salvage radical prostatectomy (SRP). Material and methods: We relied on the Surveillance, Epidemiology and End Results database (SEER, 2004-2016) to identify SRP patients of all race/ethnicity background. Univariate and multivariate Cox regression models addressed CSM according to race/ethnicity. Results: Of 426 assessable SRP patients, Caucasians accounted for 299 (69.9%) vs. 68 (15.9%) African-Americans vs. 39 (9.1%) Hispanics vs. 20 (4.7%) Asians. At diagnosis, African-Americans (64 years) were younger than Caucasians (66 years), but not younger than Hispanics (66 years) and Asians (67 years). PSA at diagnosis was significantly higher in African-Americans (13.2 ng/ml), Hispanics (13.0 ng/ml), and Asians (12.2 ng/ml) than in Caucasians (7.8 ng/ml, p = 0.01). Moreover, the distribution of African-Americans (10.3%-36.6%) and Hispanics (0%-15.8%) varied according to SEER region. The 10-year CSM was 46.5% in African-Americans vs. 22.4% in Caucasians vs. 15.4% in Hispanics vs. 15.0% in Asians. After multivariate adjustment (for age, clinical T stage, lymph node dissection status), African-American race/ethnicity was an independent predictor of higher CSM (HR: 2.2, p < 0.01), but not Hispanic or Asian race/ethnicity. The independent effect of African-American race/ethnicity did not persist after further adjustment for PSA. Conclusion: African-Americans treated with SRP are at higher risk of CSM than other racial/ethnic groups and also exhibited the highest baseline PSA. The independent effect of African-American race/ethnicity on higher CSM no longer applies after PSA adjustment since higher PSA represents a distinguishing feature in African-American patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023485
003      
CZ-PrNML
005      
20221031095210.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2022.874945 $2 doi
035    __
$a (PubMed)36059656
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Wenzel, Mike $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
245    14
$a The effect of race/ethnicity on cancer-specific mortality after salvage radical prostatectomy / $c M. Wenzel, C. Würnschimmel, L. Nocera, C. Colla Ruvolo, B. Hoeh, Z. Tian, SF. Shariat, F. Saad, A. Briganti, M. Graefen, F. Preisser, A. Becker, P. Mandel, FKH. Chun, PI. Karakiewicz
520    9_
$a Background: To test the effect of race/ethnicity on cancer-specific mortality (CSM) after salvage radical prostatectomy (SRP). Material and methods: We relied on the Surveillance, Epidemiology and End Results database (SEER, 2004-2016) to identify SRP patients of all race/ethnicity background. Univariate and multivariate Cox regression models addressed CSM according to race/ethnicity. Results: Of 426 assessable SRP patients, Caucasians accounted for 299 (69.9%) vs. 68 (15.9%) African-Americans vs. 39 (9.1%) Hispanics vs. 20 (4.7%) Asians. At diagnosis, African-Americans (64 years) were younger than Caucasians (66 years), but not younger than Hispanics (66 years) and Asians (67 years). PSA at diagnosis was significantly higher in African-Americans (13.2 ng/ml), Hispanics (13.0 ng/ml), and Asians (12.2 ng/ml) than in Caucasians (7.8 ng/ml, p = 0.01). Moreover, the distribution of African-Americans (10.3%-36.6%) and Hispanics (0%-15.8%) varied according to SEER region. The 10-year CSM was 46.5% in African-Americans vs. 22.4% in Caucasians vs. 15.4% in Hispanics vs. 15.0% in Asians. After multivariate adjustment (for age, clinical T stage, lymph node dissection status), African-American race/ethnicity was an independent predictor of higher CSM (HR: 2.2, p < 0.01), but not Hispanic or Asian race/ethnicity. The independent effect of African-American race/ethnicity did not persist after further adjustment for PSA. Conclusion: African-Americans treated with SRP are at higher risk of CSM than other racial/ethnic groups and also exhibited the highest baseline PSA. The independent effect of African-American race/ethnicity on higher CSM no longer applies after PSA adjustment since higher PSA represents a distinguishing feature in African-American patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Würnschimmel, Christoph $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Nocera, Luigi $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Colla Ruvolo, Claudia $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada $u Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy
700    1_
$a Hoeh, Benedikt $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Departments of Urology, Weill Cornell Medical College, New York, NY, United States $u Department of Urology, University of Texas Southwestern, Dallas, TX, United States $u Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czechia $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
700    1_
$a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Graefen, Markus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Preisser, Felix $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Becker, Andreas $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Mandel, Philipp $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 12, č. - (2022), s. 874945
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36059656 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20221031095208 $b ABA008
999    __
$a ind $b bmc $g 1853884 $s 1174773
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c - $d 874945 $e 20220819 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20221010

Najít záznam

Citační ukazatele

Možnosti archivace